fda warning letters glp-1 october 2025 news Issues Warnings Against Illegal Marketing Diabetes advocacy group discourages use

GLP-1 receptor agonists, such as semaglutide (sold under the brand name Ozempic or Wegovy) and tirzepatide (brand name Mounjaro or Zepbound), are medications originally developed for diabetes and now approved for chronic weight management at specific doses

A moderate increase in protein consumption can help preserve muscle mass during weight loss

Meals become smaller naturally

A lower mortality in the GLP-1 RA group would expectedly lead to an underestimation of the fracture risk in that group, thereby exaggerating a protective effect of GLP-1 RAs

The FDA previously allowed compounded tirzepatide to be made due to a national shortage, but that shortage has been resolved, and pharmacies and outsourcing facilities are no longer allowed to compound, distribute, or dispense compounded GLP-1 medications, including tirzepatide